Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

RMHB has retained turn-round specialists well versed in the restructuring of small and large companies both private and public ... finished goods inventory on their own brands and providing shorter ...

Companies can upset customers who are loyal to a specific version of a product, pushing them to switch to another brand or stores’ private-label versions. Cuts can also create tension with retailers ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

Emerging large players in the consumer healthcare space, including Haleon and Kenvue, have the resources to expand their portfolios and displace smaller brands that Prestige owns. We believe Prestige ...

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.